Navigation Links
Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights
Date:3/12/2008

o shown clinical activity in a range of skeletal diseases, including bone metastasis, Paget's disease and osteoporosis. An oral dosing regimen offers the potential to exploit the advantages of this compound, which include broad potential activity and convenient administration.

Tesetaxel

Tesetaxel, an oral taxane that is the latest addition to the Genta oncology portfolio, was recently obtained via in-licensing of its worldwide rights. Tesetaxel was specifically developed to avoid key problems associated with other taxanes (such as paclitaxel [Taxol(R); Bristol Myers Squibb] and docetaxel [Taxotere(R); sanofi Aventis]), including severe infusion reactions, peripheral neuropathy, and acquired drug resistance. More than 250 patients worldwide have received tesetaxel, and the drug has demonstrated anticancer activity in several clinical trials. Due to the occurrence of several fatalities related to neutropenia, the drug is currently on clinical hold in the U.S. Based upon guidance from FDA, Genta has worked with the former sponsor to develop a strategy that is intended to lift the clinical hold, thereby enabling clinical testing to resume. If further studies document efficacy and safety, tesetaxel offers substantial opportunities to improve convenience, safety, and activity for patients who are currently receiving conventional taxanes.

C-myb Antisense

An antisense drug directed against c-myb, a master regulatory proto- oncogene, is the Company's earliest stage clinical program. In 2007, a new dose-ranging Phase 1 trial of c-myb antisense was initiated at the University of Pennsylvania. The trial is currently open to accrual and is expected to be completed later this year after identification of the MTD.

Financial Information

The Company reported a net loss of $1.7 million or $0.06 per share for the fourth quarter of 2007, compared with a net loss of $17.3 million or $0.68 per share for the fourth quarter of 2006. For the year en
'/>"/>

SOURCE Genta Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Innocoll Announces Dosing of First Patient in Second US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections
2. Innocoll Announces Dosing of First Patient in US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections in Cardiac Surgery Patients
3. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Mildly Infected Diabetic Foot Ulcers
4. Genta Clinical Programs Featured at American Society of Hematology Meeting
5. Genta Completes Initial Clinical Dosing of G4544, a New Oral Drug for Bone Diseases
6. Genta Incorporated Announces Third Quarter 2007 Financial Results
7. Genta Initiates First Clinical Trial with New Oral Drug (G4544) to Treat Bone Disease
8. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
9. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
10. Progen Announces Commencement of Global Phase 3 Study for PI-88 in Post- Resection Liver Cancer
11. Inclinix Announces New Patent for Expert System Platform
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... , Sept. 17, 2014 The ... the last decade due to the recession, ... and technological advancements. This BCC Research report ... segments of the ambulance and emergency medical ... blood and hemorrhage control devices, equipment used ...
(Date:9/17/2014)... BURLINGTON, Mass. , Sept. 17, 2014 ... Crohn,s disease/ulcerative colitis (CD/UC) patients eligible for ... currently receive a biologic. Surveyed gastroenterologists cite ... main reason for low penetration rates, followed ... CD and UC patients receiving biologics, Janssen ...
(Date:9/17/2014)... NEW YORK and SAN JOSE, Calif. ... Systems has been named as a laureate of The ... recognized for applying technology to benefit humanity and spark global ... Museum of Innovation, and presented by Applied Materials, Inc., selected ... Award category. Photo - http://photos.prnewswire.com/prnh/20140917/146680 ...
Breaking Medicine Technology:Ambulance and Emergency Equipment: Global Markets 2Ambulance and Emergency Equipment: Global Markets 3Ambulance and Emergency Equipment: Global Markets 4The Majority of Surveyed Gastroenterologists Agree that Biologics Should be Prescribed to More Patients in the Crohn's Disease and Ulcerative Colitis Treatment Paradigm 2The Majority of Surveyed Gastroenterologists Agree that Biologics Should be Prescribed to More Patients in the Crohn's Disease and Ulcerative Colitis Treatment Paradigm 3Gradian Health Systems Named A 2014 Laureate of The Tech Awards 2Gradian Health Systems Named A 2014 Laureate of The Tech Awards 3
... Mass., April 29, 2012  Haemonetics Corporation (NYSE: ... definitive agreement to acquire the business assets of Hemerus ... for the collection of whole blood, and processing and ... clinical trials and has submitted a New Drug Application ...
... Calif., April 27, 2012  Ultra Clean Holdings, ...  of critical subsystems, for the semiconductor capital equipment, ... announced that Clarence Granger, Chairman and Chief Executive ... address the Jefferies 2012 Global Technology, Media & ...
Cached Medicine Technology:Haemonetics Signs Definitive Agreement To Acquire Hemerus Medical, LLC 2Haemonetics Signs Definitive Agreement To Acquire Hemerus Medical, LLC 3Haemonetics Signs Definitive Agreement To Acquire Hemerus Medical, LLC 4
(Date:9/17/2014)... Final Cut Pro X plugin developers have announced a new ... , “ProBlue 5k is a compilation of anamorphic flares that ... Christina Austin, CEO of Pixel Film Studios. “Blurring the line ... changer.” , ProBlue 5k is the ultimate Ultra High Definition ... footage compilation of over 100 anamorphic flares can be applied ...
(Date:9/17/2014)... Las Vegas, NV (PRWEB) September 17, 2014 ... by Dr. Dan Ritchie and Dr. Cody Sipe that is ... quality of life and longevity has caught the attention of ... ask most people in their 50s, 60s, or even 70s ... quality of life on a day-to-day basis, they would probably ...
(Date:9/17/2014)... the ends of chromosomes could hold the key to a ... skin cancer according to new research from the University ... new genetic risk factor for melanoma. , It is well ... of those most at risk of developing melanoma. For example, ... they burn more easily. , It now appears that another ...
(Date:9/17/2014)... In Pretrial Order #139 (Scheduling of Discovery ... would be beneficial in this [MDL].” Accordingly, the court ... end of December,” the order further provides, “the court ... , “The plain import of this order is ... to be discussed as these cases progress toward trial,” ...
(Date:9/17/2014)... blood test that measures DNA from a prostate cancer ... the state of a man,s disease, a new study ... could reveal when treatment for advanced prostate cancer ... researchers suggested. "Our study showed that a steroid ... often initially very effective started to activate harmful mutations ...
Breaking Medicine News(10 mins):Health News:A New Plugin Entitled ProBlue 5k Was Released Today from Pixel Film Studios Exclusively for Final Cut Pro X 2Health News:Functional Fitness Solution: Review Exposes Dr. Dan Ritchie and Dr. Cody Sipe’s Guide to Everyday Fitness for Longevity 2Health News:Chromosome buffers hold key to better melanoma understanding 2Health News:Transvaginal Mesh Lawsuit News: New Order in C.R. Bard MDL Sets Schedule of Conferences for September to December, the Rottenstein Law Group LLP Reports 2Health News:DNA Blood Test Might Identify Status of Prostate Cancer 2
... SAGE Launch Clinical Psychological Science ,Association for Psychological ... Angeles, CA (April 23, 2012) The Association for ... Clinical Psychological Science , a new peer-reviewed journal focused ... venue for cutting-edge research across a wide range of ...
... Guy, M.D., professor of ophthalmology at Bascom Palmer Eye ... Medicine, has pioneered a novel technological treatment for Leber ... causes rapid, permanent, and bilateral loss of vision in ... Genetic mutations in the mitochondria (part of the ...
... 23 (HealthDay News) -- Teen drivers and passengers are more likely ... belt laws, often promoted as "click it or ticket" laws, a ... and ticket drivers solely for not wearing a seat belt. Under ... are stopped for other reasons, such as speeding. Primary seat ...
... The Global Cardiovascular Disease Taskforce called on the 11,000 ... cardiovascular disease (CVD) community at large, to support the ... disease (NCD) mortality by 25 per cent by 2025. ... from the world,s largest CVD organizations including the American ...
... Hispanic lung cancer patients seem to live longer than ... Cancer , a peer-reviewed journal of the American Cancer ... types of cancer, certain yet-to-be-defined genetic and/or environmental factors ... studies that look at ethnic and racial disparities in ...
... Health (NIH) scientists and their colleagues in China have ... called sasX , which plays a pivotal role ... in most of Asia. Senior author Michael Otto, Ph.D., ... says these findings illustrate at the molecular level how ...
Cached Medicine News:Health News:Association for Psychological Science, SAGE launch Clinical Psychological Science 2Health News:Bascom Palmer Eye Institute announces breakthrough for degenerative vision disorder 2Health News:Stricter Seat Belt Laws Get Teens to Buckle Up, Study Shows 2Health News:Global CVD leaders call the world to action - 25 by 2025 - from the World Congress of Cardiology 2Health News:Hispanic lung cancer patients tend to live longer than blacks and whites 2Health News:NIH scientists link quickly spreading gene to Asian MRSA epidemic 2
Tracheal Suction Latex Rubber Catheters - Funnel End...
Rubber bronchial coude catheter, X-ray opaque, one eye, whistle tip....
KCIs KinAir IV combines Advanced Pressure Relief Therapy with a manual wound care turn to provide optimum skin care and patient,positioning....
... The Paradigm LD400 FT is an affordable ... exam time by at least 40%. It has ... It features rapid setup and easy two-button operation ... friendly. The LD 400 FT is the workhorse ...
Medicine Products: